STUDIES OF CANCER IN FAMILIES

佛蒙特州癌症中心的家族性癌症项目是一个 多学科的临床和研究计划，解决的需求 患癌风险过高的患者和家庭。 程序 协调高风险干预、筛查方案和研究 包括从高风险患者采集标本的方案， 和他们的家人进行基因研究。 该计划的重点是 多种多样，包括所有已知的家族性癌症综合征，以及 家庭或个人可能有明显的过度风险， 符合特定的综合征 在1996年1月12日至1997年11月30日期间， 新的家庭提到了该方案。 大多数转介的案件 来自肿瘤学家;在所有转诊病例中， 显示，大约25%的人处于最高风险类别的会议中， 一种已知的癌症家族综合征 这些研究的数据表明， 只有三分之一的接触导致后续行动，包括遗传 咨询或其他形式的干预。 最常见的两 涉及FCP的综合征是家族性乳腺癌和卵巢癌， 遗传性非息肉病性结肠癌，一起构成大约 三分之二的转介。 有趣的是，只有10%的人 或符合家族性乳腺癌或结肠癌标准的家庭 癌症实际上会一直持续到接受基因治疗的地步， 测试和咨询。 在这项研究中，UVM GCRC已被用作静脉切开术的部位， 例 GCRC服务允许采集血液样本， 转移到机构的分子诊断实验室， 制备样品并参考各种研究方案， 进一步分析。 预计将有150-200名新的转诊病例 在1997年1月12日至1998年11月30日期间。 GCRC服务对于 本研究方案通过促进血液标本的采集， 许多患者不愿意参加这项研究，如果不参加， 与研究标本收集相关的口袋费用将是 招致的。

The Familial Cancer Program of the Vermont Cancer Center is a multidisciplinary Clinical and research program that addresses the needs of patients and families with an excess risk for cancer. The program coordinates high-risk intervention, screening protocols, and research protocols that include collection of specimens from high risk patients, and their family members for genetic studies. The focus of the program is diverse, including all known familial cancer syndromes, as well as families or individuals who may have apparent excess risk that does not fit a defined syndrome. During the period 12/1/96-11/30/97 there were 160 new families referred to the program. The majority of the referrals have been from oncologists; among all referrals, triage review of cases revealed that approximately 25% were in the highest risk category meeting a known cancer familial syndrome. Data from these studies indicate that only one-third of all contacts result in follow-up to include genetic counseling or some other form of intervention. The two most common syndromes referred to the FCP are familial breast and ovarian cancer and hereditary nonpolyposis colon cancer, together making up approximately two-thirds of all referrals. Interestingly, only 10% of those individuals or families meeting established criteria for familial breast or colon cancer will actually follow through to the point of receiving genetic testing and counseling. In this research, the UVM GCRC has been used as the site of phlebotomy for cases. GCRC services allowed collection of the blood specimen and transfer to the Institution's Molecular Diagnostic laboratory, where samples were prepared and referred to various research protocols for further analysis. It is anticipated that 150-200 new referrals will occur during the period 12/1/97-11/30/98. GCRC services have been critical to this research protocol by facilitating collection of blood specimens, as many patients have been reluctant to participate in this study if out-of- pocket costs associated with research specimen collection would be incurred.